Navigation Links
Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
Date:8/8/2008

EAST SETAUKET, N.Y., Aug. 8 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today that lead compounds from each of two different types of drugs being developed as potential treatment for specific types of brain cancers have activity against human pancreatic cancers in a mouse model.

Dr. John S. Kovach, President and CEO of Lixte, said, "Lixte previously reported that lead compounds from each of two different classes of pharmacologic agents have significant inhibitory activity against several types of human cancers in the test tube and against brain cancers in animal models. We have now found that two different lead compounds also have statistically significant activity against human pancreatic cancer cells growing in mice. These are early studies and there is no evidence that these drugs are able to eliminate pancreatic cancers but rather slow their growth. We are encouraged, however, that two classes of our drugs have activity against this devastating cancer in addition to glioblastoma multiforme, the most common and most malignant form of brain cancer."

About Lixte Biotechnology Holdings, Inc.:

Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers.

Forward-Looking Statements:

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
2. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
3. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
4. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
7. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)....C., Nov. 6 Chimerix, Inc., a biop...ntiviral therapeutics to address life-threatening ...the company,s lead antiviral compound, CMX001, to ... Health Security Initiative (GHSI). CMX001 is a b...the treatment of smallpox, as well as other seriou...
(Date:11/6/2009)...re-FirstCall/ -- Caraco Pharmaceutical Laboratorie...tromethamine ophthalmic solution, 0.5% following a...ration (FDA) for Sun Pharma,s Abbreviated New Drug...lmic solution on the first day following patent ex...cally equivalent to Acular® Ophthalmic Soluti...
(Date:11/5/2009)...swire/ -- Althea Technologies, Inc., a leading pro...r biopharmaceutical products announced the additio...pany,s platform of services, which will be oversee...tor of Formulation Development. This investment in... scientists, along with new laboratory facilities ...
Breaking Medicine Technology:Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2RiversEdge BioVentures LLC to Provide Advisory and Investment Services in Life Sciences 13993 1RiversEdge BioVentures LLC to Provide Advisory and Investment Services in Life Sciences 13993 2GENova to acquire three new drug target patents worth in excess of 241 billion in royalty fees 56862 1GENova to acquire three new drug target patents worth in excess of 241 billion in royalty fees 56862 2GENova to acquire three new drug target patents worth in excess of 241 billion in royalty fees 56862 3Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 56858 1Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 56858 2Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 56858 3Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 56858 4
...l Therapeutics (CTI),(Nasdaq and MTA: CTIC) announ...nd Drug Administration (FDA), CTI expects to begin...) and request priority review for pixantrone to tr...L) in the first quarter of 2009.,If granted priori... the end of,2009. , "This communication from t...
...t Angiolix has similar efficacy to Avastin alone a...th potentially less side-effects; study validates ...DALLAS, Jan. 26 ACCESS PHARMACEUTICALS, INC. (OTC...k on its proprietary humanized monoclonal antibody... with high affinity to the its target, lactadherin...
Other Medicine Technology:Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission 2Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission 3Access Pharmaceuticals Presents new Combination Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents new Combination Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3
(Date:11/8/2009)...SNewswire/ -- The American Public Health Associati...visions in the health reform bill passed last nigh...the House takes important steps toward universal c...d moving our health system from one that focuses o... people healthy," said Georges C. Benjamin, MD, FA...
(Date:11/8/2009)...es self-assurance, research finds , , SU...ave been right when she told you to sit up straigh...ake you feel more confident about your thoughts. ...ght gives a good impression to other people," Rich... professor at Ohio State University, said in a uni...
(Date:11/8/2009)...e game later, doctors say , , SUNDAY, No...k of the NFL this season, sidelining such stars as...arker. , Officials at the American Podiatric Me...c Sports Medicine are warning athletes to take car...otball and lacrosse. , "Many fall sports athlet...
(Date:11/8/2009)...ewswire/ -- Speaker Nancy Pelosi and Democratic le...passage of H.R. 3962, the Affordable Health Care f...to 215. Below are the Speaker,s opening remarks: ...a call from the President of the United States, Ba...or the American people. I thank the President for ...
(Date:11/8/2009)...d "Preventing and Healing AIDS Through Our In...at AIDS is a result of multiple, repeated and chro...em stressor agents, which can be either chemical, ... , Oakland, CA (PRWEB) No...l biologists, physicians, chemists and other scien...
Breaking Medicine News(10 mins):Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2Health News:Good Posture May Inspire Confidence 2Health News:Rx for Fall Foot Injuries 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3
...ty researchers have identified the role of a key e... the way for new target therapies to reduce plaque...predict a patients susceptibility to heart disease...plaques. , Heart disease results from the format...
...s for respiratory health , , WEDNESDAY, Oc...ngs, a couple of drinks a day may help keep the do...le evidence has mounted that a daily dose of alcoh... the possible protective effect of alcohol involvi...
...ompany Becomes First to Leverage Zagat,s, Expertis...de Feedback and Rate Experiences Using Zag...W YORK, Oct. 24 WellPoint, Inc., the,nation,s lar... their physician experiences with others. A first ...
...ydrate, a novel,medical humidifier, was awarded a ... October 18, 2007. PARI Innovative Manufacturers, ...rs, developed the PARI Hydrate to,revolutionize th...The award, selected by an independent panel of jud...
...ced in healthy volunteers, according to a study by...Diego (UCSD) Center for Medical Cannabis Research ...may be more. , In the placebo controlled study of...results suggest a "therapeutic window" for cannabi...
... the,leading cause of death in the United States, ...izophrenia. The November 2007 issue of the Harvard...great for people with,schizophrenia and what can t... They are also less,likely to receive good prevent...
Other Medicine News:Health News:Role of a key enzyme in reducing heart disease identified 2Health News:Drink or Two a Day May Help Lungs 2Health News:Drink or Two a Day May Help Lungs 3Health News:Drink or Two a Day May Help Lungs 4Health News:WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 2Health News:WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 3Health News:PARI's Hydrate Wins Prestigious R&D 100 Award 2Health News:Smoked cannabis proven effective in treating neuropathic pain 2Health News:People with Schizophrenia More Likely to Die of Heart Disease, Reports the Harvard Mental Health Letter 2
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
Medicine Products: